A lack of exposure to respiratory syncytial virus in the first 2 years of COVID-19 may have led to the global resurgence of the virus in 2022 and 2023.
An ongoing clinical trial shows a 94.1% reduction in risk of severe illness.
RSV activity began in the southeast and worked its way north and west. In its Marburg notice, the CDC said there is no evidence so far that the two outbreaks are connected.
Nearly two-thirds of patients hospitalized with flu, RSV, or COVID-19 received antibiotics, but they had a higher risk of death than those who didn't.
The advisory group's strong approval comes a day after it recommended Pfizer's RSV vaccine on a closer vote for the same age-group.
The group raised concerns about a small number of Guillain-Barre syndrome cases in vaccine recipients and wanted more data, especially on efficacy in those at highest risk.
The Department of Energy, with "low confidence," says SARS-CoV-2 may have come from a lab, and a controversial doctors groups touts ivermectin for the flu and RSV.
The FDA has granted RSVpreF priority review for use in pregnant women to help protect babies against the virus.
In another COVID development, the FDA pulled its EUA for Evusheld, the last available monoclonal antibody treatment, due to weak activity against the newer circulating subvariants.
Amid rising flu activity causing decade-high hospitalization rates, COVID-19 markers are also climbing.
